These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 25760242)

  • 1. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
    Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
    Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
    Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
    Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
    Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
    Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.
    Miyazaki K; Yamaguchi M; Imai H; Kobayashi K; Tamaru S; Kobayashi T; Shiku H; Katayama N
    Int J Hematol; 2015 Aug; 102(2):188-94. PubMed ID: 26009281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
    Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
    Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rare CD5-positive subgroup of diffuse large B-cell lymphoma - clinical, morphological and immunophenotypic features in Polish patients.
    Woźnialis N; Gierej B; Popławska L; Ziarkiewicz M; Kulczycka E; Ziarkiewicz-Wróblewska B
    Pol J Pathol; 2016; 67(3):235-243. PubMed ID: 28155972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
    Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
    Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization.
    Karnan S; Tagawa H; Suzuki R; Suguro M; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
    Genes Chromosomes Cancer; 2004 Jan; 39(1):77-81. PubMed ID: 14603444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical analysis of 10 patients with de novo CD5 positive diffuse large B cell lymphoma].
    Zhang Q; Zhang HY; Zhong FL; Zhang WL; Xu L; Feng J; Meng QX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):399-402. PubMed ID: 23628041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
    Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
    Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study.
    Sang W; Ma Y; Wang X; Ma Y; Shen Z; Gu W; Wang F; Ye J; Zhang C; Miao Y; Xu C; Liu Q; Li B; Tu J; Wang C; Shi Y; Sun S; Yan D; Song X; Sun C; Shao Y; Xu L; Li Z; Ma D; Xu K; Young KH; Liu H
    Am J Surg Pathol; 2022 Nov; 46(11):1533-1544. PubMed ID: 36006771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome).
    Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
    Am J Clin Pathol; 2009 Mar; 131(3):339-46. PubMed ID: 19228640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
    Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
    Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
    Slack GW; Steidl C; Sehn LH; Gascoyne RD
    Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De Novo CD5
    Xu Y; Sun W; Li F
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e782-e790. PubMed ID: 32694049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
    Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
    Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
    Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
    Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.